Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
CYTH

CYTH - Cyclo Therapeutics, Inc. Stock Price, Fair Value and News

$5.61-0.04 (-0.71%)
Market Closed

8/100

CYTH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

8/100

CYTH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CYTH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CYTH Price Action

Last 7 days

-4.4%

Last 30 days

-18.7%

Last 90 days

-23.2%

Trailing 12 Months

23.8%

CYTH RSI Chart

CYTH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

CYTH Valuation

CYTH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

CYTH Fundamentals

CYTH Revenue

CYTH Earnings

CYTH Profitability

CYTH Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20242.1M2.2M3.1M0
20232.8M2.5M2.7M1.9M
20221.4M1.7M1.7M2.5M
20211.0M1.2M1.6M1.5M
20201.1M1.0M835.0K989.6K
20191.0M957.9K1.0M1.0M
20181.1M957.1K940.4K1.0M
20171.5M1.6M1.6M1.2M
20161.1M1.1M1.1M1.5M
20151.2M1.4M1.2M950.5K
20141.7M1.1M1.4M1.6M
20131.2M1.7M1.8M1.7M
20121.2M941.3K867.4K988.0K
2011853.0K912.6K972.2K1.0M
2010000793.4K
Get all data in R, Python etc through our Historical Stock Data APIs

About Cyclo Therapeutics, Inc.

CYTH
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
 CEO
 WEBSITEhttps://cyclotherapeutics.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES9

Cyclo Therapeutics, Inc. Frequently Asked Questions

CYTH is the stock ticker symbol of Cyclo Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

In the past 10 years, Cyclo Therapeutics, Inc. has provided -0.151 (multiply by 100 for percentage) rate of return.